{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:47:36Z","timestamp":1740134856160,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,30]]},"DOI":"10.1182\/blood.2024024295","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T15:31:25Z","timestamp":1717083085000},"page":"2219-2221","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["RNAing toward a new therapy for hemophilia"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7578-4231","authenticated-orcid":false,"given":"Bhavya S.","family":"Doshi","sequence":"first","affiliation":[{"name":"1Children\u2019s Hospital of Philadelphia"},{"name":"2University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-9415","authenticated-orcid":false,"suffix":"Jr","given":"Robert F.","family":"Sidonio","sequence":"additional","affiliation":[{"name":"3Children\u2019s Healthcare of Atlanta"},{"name":"4Emory University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"22","key":"2024053015310765300_bib1","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2023021864","article-title":"Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA\/CFC prophylaxis: the ATLAS-PPX trial","volume":"143","author":"Kenet","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2024053015310765300_bib2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024053015310765300_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjh.18379","article-title":"Current and future therapies for haemophilia\u2014beyond factor replacement therapies","volume":"200","author":"Nogami","year":"2023","journal-title":"Br J Haematol"},{"issue":"16","key":"2024053015310765300_bib4","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"2024053015310765300_bib5","doi-asserted-by":"crossref","first-page":"670526","DOI":"10.3389\/fmed.2021.670526","article-title":"Progress in the development of anti-tissue factor pathway inhibitors for haemophilia management","volume":"8","author":"Mahlangu","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"2024053015310765300_bib6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"},{"issue":"4","key":"2024053015310765300_bib7","doi-asserted-by":"crossref","first-page":"100179","DOI":"10.1016\/j.rpth.2023.100179","article-title":"Antithrombin lowering in hemophilia: a closer look at fitusiran","volume":"7","author":"Young","year":"2023","journal-title":"Res\u00a0Pract Thromb Haemost"},{"issue":"5","key":"2024053015310765300_bib8","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.thromres.2015.03.010","article-title":"Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies","volume":"135","author":"Di Minno","year":"2015","journal-title":"Thromb Res"},{"issue":"1","key":"2024053015310765300_bib9","doi-asserted-by":"crossref","first-page":"100007","DOI":"10.1016\/j.rpth.2022.100007","article-title":"Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: a scoping review","volume":"7","author":"Shapiro","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"2024053015310765300_bib10","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jtha.2023.01.010","article-title":"Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021","volume":"21","author":"Abbattista","year":"2023","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/22\/2219\/2226672\/blood_bld-2024-024295-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/22\/2219\/2226672\/blood_bld-2024-024295-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T15:31:30Z","timestamp":1717083090000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/22\/2219\/516162\/RNAing-toward-a-new-therapy-for-hemophilia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":10,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2024,5,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024295","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}